Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate PDS Biotechnology Corporation before investing.

In this article, we go over a few key elements for understanding PDS Biotechnology Corporation’s stock price such as:

• PDS Biotechnology Corporation’s current stock price and volume
• Why PDS Biotechnology Corporation’s stock price changed recently
• Upgrades and downgrades for PDSB from analysts
• PDSB’s stock price momentum as measured by its relative strength

About PDS Biotechnology Corporation (PDSB)

Before we jump into PDS Biotechnology Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company’s lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.

Want to learn more about PDS Biotechnology Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about PDS Biotechnology Corporation.

PDS Biotechnology Corporation’s Stock Price as of Market Close

As of May 12, 2026, 4:00 PM, CST, PDS Biotechnology Corporation’s stock price was $1.100.

PDS Biotechnology Corporation is down 15.38% from its previous closing price of $1.300.

During the last market session, PDS Biotechnology Corporation’s stock traded between $1.050 and $1.300. Currently, there are approximately 51.59 million shares outstanding for PDS Biotechnology Corporation.

PDS Biotechnology Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

PDS Biotechnology Corporation Stock Price History

PDS Biotechnology Corporation’s (PDSB) price is currently up 13.05% so far this month.

During the month of May, PDS Biotechnology Corporation’s stock price has reached a high of $1.350 and a low of $0.956.

Over the last year, PDS Biotechnology Corporation has hit prices as high as $1.915 and as low as $0.507. Year to date, PDS Biotechnology Corporation’s stock is up 42.89%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused PDS Biotechnology Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 12, 2026, there were analysts who downgraded PDS Biotechnology Corporation’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate PDS Biotechnology Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on PDS Biotechnology Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about PDS Biotechnology Corporation (PDSB) by visiting AAII Stock Evaluator.

Relative Price Strength of PDS Biotechnology Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 12, 2026, PDS Biotechnology Corporation has a weighted four-quarter relative price strength of 4.61%, which translates to a Momentum Score of 72 and is considered to be Strong.

Want to learn more about how PDS Biotechnology Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

PDS Biotechnology Corporation Stock Price: Bottom Line

As of May 12, 2026, PDS Biotechnology Corporation’s stock price is $1.100, which is down 15.38% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like PDS Biotechnology Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.